Research programme: autoimmune disorder therapeutics - Array BioPharma/Biogen
Latest Information Update: 09 Apr 2015
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Biogen
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 28 May 2014 Preclinical trials in Autoimmune disorders in USA (unspecified route)